Jump to:

Patient Resources

Display:
A - Z All Fact Sheets
Travel Fact Sheets

Diphtheria

Diphtheria is caused by a bacteria which lives in the respiratory tract of many people without causing disease. These people are called carriers and do not become infected because they have either been immunised or have immunity from having had the disease.

Symptoms include a sore throat with a greyish membrane. In severe cases the neck tissue may become swollen and affect swallowing and breathing. In tropical countries the infection may occur in skin ulcers. After 2-6 weeks, the effects of a toxin produced by the bacteria become apparent with severe muscle weakness, mainly affecting the muscles of the head and neck. Inflammation of the heart muscle may cause heart failure.

How do you catch diphtheria?

Diphtheria can spread through droplet infection from coughing and sneezing. Contact with articles soiled by infected persons may also transmit the wound infection.

Incubation period:

Usually 2-5 days, but it can be longer.

Prevention:

Effective protection is gained through immunisation. In the UK in 1940 routine immunisation against diphtheria was introduced in childhood. Travellers who are recommended to have the vaccine for travel to high risk areas require a booster dose every 10 years if a primary course has previously been given. In 2002, the Dept of Health recommended that people requiring a tetanus booster should receive the combined tetanus and diphtheria vaccine in response to waning immunity to diphtheria in the adult population.

Treatment:

Diphtheria is treated with an anti-toxin and antibiotics (usually penicillin or erythromycin). Treatment should not be delayed until laboratory confirmation is available.

Fact sheet written by:

MASTA

MASTA are specialists in travel health services. Healthcare professionals can access its daily updated database of vaccine and travel health advice by registering at www.masta.org (fee applies). Travellers can search for advice and information and find a MASTA Travel Clinic at www.masta-travel-health.com

Latest Guidelines

Infliximab (review) and adalimumab for the treatment of Crohn's disease

Technology Appraisal Guidance No. 187 Source: National Institute for Health and...

Febuxostat for the Management of Hyperuricaemia in People with Gout

Technology Appraisal Guidance No. 164 Source: National Institute for Health and Clinical...

Trabectedin for the Treatment of Advanced Soft Tissue Sarcoma

Technology Appraisal Guidance No. 185 Source: National Institute for Health and Clinical...

Certolizumab Pegol for the Treatment of Rheumatoid Arthritis

Technology Appraisal Guidance No. 186 Source: National Institute for Health and Clinical...

Topotecan for the Treatment of Relapsed Small-Cell Lung Cancer

Technology Appraisal Guidance No. 184 Source: National Institute for Health and Clinical...

 

GP Curriculum Centre

Educational resource for the learning and teaching of the
GP curriculum

Click here to read more

Deleted products

Cumulative list of products discontinued from the UK market
in 2010

Click here to read more

Treating psoriasis

Healthcare Republic resource centre for diagnosing and managing psoriasis

Click here to read more

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

 

Back to top